Home > Research > Publications & Outputs > Towards a national genomics medicine service

Links

Text available via DOI:

View graph of relations

Towards a national genomics medicine service: the challenges facing clinical-research hybrid practices and the case of the 100,000 genomes project

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Towards a national genomics medicine service: the challenges facing clinical-research hybrid practices and the case of the 100,000 genomes project. / Dheensa, Sandi; Samuel, Gabrielle; Lucassen, Anneka M. et al.
In: Journal of Medical Ethics, Vol. 44, No. 6, 06.2018, p. 397-403.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Dheensa S, Samuel G, Lucassen AM, Farsides B. Towards a national genomics medicine service: the challenges facing clinical-research hybrid practices and the case of the 100,000 genomes project. Journal of Medical Ethics. 2018 Jun;44(6):397-403. Epub 2018 Mar 1. doi: 10.1136/medethics-2017-104588

Author

Dheensa, Sandi ; Samuel, Gabrielle ; Lucassen, Anneka M. et al. / Towards a national genomics medicine service : the challenges facing clinical-research hybrid practices and the case of the 100,000 genomes project. In: Journal of Medical Ethics. 2018 ; Vol. 44, No. 6. pp. 397-403.

Bibtex

@article{07bf8a1212f44ec98f39d9f871969bf3,
title = "Towards a national genomics medicine service: the challenges facing clinical-research hybrid practices and the case of the 100,000 genomes project",
abstract = "Clinical practice and research are governed by distinct rules and regulations and have different approaches to, for example, consent and providing results. However, genomics is an example of where research and clinical practice have become codependent. The 100 000 genomes project (100kGP) is a hybrid venture where a person can obtain a clinical investigation only if he or she agrees to also participate in ongoing research—including research by industry and commercial companies. In this paper, which draws on 20 interviews with professional stakeholders involved in 100kGP, we investigate the ethical issues raised by this project{\textquoteright}s hybrid nature. While some interviewees thought the hybrid nature of 100kGP was its vanguard, interviewees identified several tensions around hybrid practice: how to decide who should be able to participate; how to determine whether offering results might unduly influence participation into wide-ranging but often as yet unknown research and how to ensure that patients/families do not develop false expectations about receiving results. These areas require further debate as 100kGP moves into routine healthcare in the form of the national genomic medicine service. To address the tensions identified, we explore the appropriateness of Faden et al.{\textquoteright}s framework of ethical obligations for when research and clinical care are completely integrated. We also argue that enabling ongoing transparent and trustworthy communication between patients/families and professionals around the kinds of research that should be permitted in 100kGP will help to understand and ensure that expectations remain realistic. Our paper aims to encourage a focused discussion about these issues and to inform a new {\textquoteleft}social contract{\textquoteright} for research and clinical care in the health service.",
author = "Sandi Dheensa and Gabrielle Samuel and Lucassen, {Anneka M.} and Bobbie Farsides",
year = "2018",
month = jun,
doi = "10.1136/medethics-2017-104588",
language = "English",
volume = "44",
pages = "397--403",
journal = "Journal of Medical Ethics",
issn = "0306-6800",
publisher = "BMJ Publishing Group",
number = "6",

}

RIS

TY - JOUR

T1 - Towards a national genomics medicine service

T2 - the challenges facing clinical-research hybrid practices and the case of the 100,000 genomes project

AU - Dheensa, Sandi

AU - Samuel, Gabrielle

AU - Lucassen, Anneka M.

AU - Farsides, Bobbie

PY - 2018/6

Y1 - 2018/6

N2 - Clinical practice and research are governed by distinct rules and regulations and have different approaches to, for example, consent and providing results. However, genomics is an example of where research and clinical practice have become codependent. The 100 000 genomes project (100kGP) is a hybrid venture where a person can obtain a clinical investigation only if he or she agrees to also participate in ongoing research—including research by industry and commercial companies. In this paper, which draws on 20 interviews with professional stakeholders involved in 100kGP, we investigate the ethical issues raised by this project’s hybrid nature. While some interviewees thought the hybrid nature of 100kGP was its vanguard, interviewees identified several tensions around hybrid practice: how to decide who should be able to participate; how to determine whether offering results might unduly influence participation into wide-ranging but often as yet unknown research and how to ensure that patients/families do not develop false expectations about receiving results. These areas require further debate as 100kGP moves into routine healthcare in the form of the national genomic medicine service. To address the tensions identified, we explore the appropriateness of Faden et al.’s framework of ethical obligations for when research and clinical care are completely integrated. We also argue that enabling ongoing transparent and trustworthy communication between patients/families and professionals around the kinds of research that should be permitted in 100kGP will help to understand and ensure that expectations remain realistic. Our paper aims to encourage a focused discussion about these issues and to inform a new ‘social contract’ for research and clinical care in the health service.

AB - Clinical practice and research are governed by distinct rules and regulations and have different approaches to, for example, consent and providing results. However, genomics is an example of where research and clinical practice have become codependent. The 100 000 genomes project (100kGP) is a hybrid venture where a person can obtain a clinical investigation only if he or she agrees to also participate in ongoing research—including research by industry and commercial companies. In this paper, which draws on 20 interviews with professional stakeholders involved in 100kGP, we investigate the ethical issues raised by this project’s hybrid nature. While some interviewees thought the hybrid nature of 100kGP was its vanguard, interviewees identified several tensions around hybrid practice: how to decide who should be able to participate; how to determine whether offering results might unduly influence participation into wide-ranging but often as yet unknown research and how to ensure that patients/families do not develop false expectations about receiving results. These areas require further debate as 100kGP moves into routine healthcare in the form of the national genomic medicine service. To address the tensions identified, we explore the appropriateness of Faden et al.’s framework of ethical obligations for when research and clinical care are completely integrated. We also argue that enabling ongoing transparent and trustworthy communication between patients/families and professionals around the kinds of research that should be permitted in 100kGP will help to understand and ensure that expectations remain realistic. Our paper aims to encourage a focused discussion about these issues and to inform a new ‘social contract’ for research and clinical care in the health service.

U2 - 10.1136/medethics-2017-104588

DO - 10.1136/medethics-2017-104588

M3 - Journal article

VL - 44

SP - 397

EP - 403

JO - Journal of Medical Ethics

JF - Journal of Medical Ethics

SN - 0306-6800

IS - 6

ER -